ProCE Banner Activity

EVOLVE: Phase I/II Study of BCMA-Targeted CAR T-Cell Therapy Orvacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma

Slideset Download
Conference Coverage
BCMA-directed CAR T-cell therapy with orva-cel demonstrated robust activity in a dose-finding phase I study of heavily pretreated patients with multiple myeloma.

Released: June 02, 2020

Expiration: June 01, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono